Susquehanna Fundamental Investments LLC bought a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 182,925 shares of the company's stock, valued at approximately $1,796,000. Susquehanna Fundamental Investments LLC owned 0.32% of Ginkgo Bioworks at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in DNA. SBI Securities Co. Ltd. acquired a new stake in Ginkgo Bioworks during the 4th quarter valued at $29,000. KBC Group NV acquired a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at $31,000. KLP Kapitalforvaltning AS purchased a new stake in Ginkgo Bioworks during the 4th quarter worth about $46,000. Palumbo Wealth Management LLC purchased a new position in Ginkgo Bioworks in the 4th quarter valued at about $144,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Ginkgo Bioworks during the 4th quarter worth about $154,000. 78.63% of the stock is owned by hedge funds and other institutional investors.
Ginkgo Bioworks Stock Up 1.1 %
Shares of NYSE:DNA traded up $0.08 during trading on Friday, reaching $7.04. The stock had a trading volume of 1,049,317 shares, compared to its average volume of 1,478,624. The stock has a market cap of $408.56 million, a P/E ratio of -0.54 and a beta of 1.34. The business has a fifty day moving average price of $7.24 and a 200-day moving average price of $9.13. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $41.20.
Ginkgo Bioworks Company Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
See Also
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
